Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-036 / GOG-3123 / ENGOT-cx22 first-line maintenance study of sacituzumab tirumotecan combinations in PD-L1-positive metastatic cervical cancer
2025-521514-26-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan, pembrolizumab and bevacizumab in Cervical Cancer (CC) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more adverse events, Number of participants who discontinue study treatment due to an adverse event and 2 more. Planned start Jan 2026; status: authorised.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2025-521514-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521514-26-00.